Efficacy and safety of oral JAK1 inhibitor upadacitinib monotherapy for papulopustular rosacea: A real-world study [0.03%]
托法替布单药治疗玫瑰痤疮的疗效和安全性：一项真实世界研究
Bingyang Xu,Yuxin Qing,Yuanqin Wang et al.
Bingyang Xu et al.
Jonathan Kantor
Jonathan Kantor
Response to Metko et al, "Prevalence and risk factors of interstitial lung disease in dermatomyositis: A retrospective study" [0.03%]
对Metko等关于皮肌炎患者间质性肺病患病率和危险因素的回顾性研究的回应
Saloni Patel,Jun Kang
Saloni Patel
Mapping Melanoma Mortality Hot Spots: A Geographic Spatial Analysis of Socioeconomic and Provider Disparities [0.03%]
melanoma死亡热点分布图：社会经济及提供者差异的地域空间分析
Eli Kasheri,Brianna Sa,Garret Kraft et al.
Eli Kasheri et al.
Post-Marketing Safety Analysis of Upadacitinib in Atopic Dermatitis: An FDA Adverse Reporting System (FAERS) Review of Boxed Warning Related Adverse Events [0.03%]
乌帕替尼治疗特应性皮炎上市后安全性分析：对黑框警告相关不良事件的FDA不良事件报告系统（FAERS）审查
Aditya Joshi,Lauren Gawey,Muhammad Rahman et al.
Aditya Joshi et al.
Impact of personal sun sensitivity and UV radiation on the association between blistering sunburns and melanoma [0.03%]
个人对阳光的敏感度及紫外线辐射与严重晒伤和黑色素瘤关联的影响研究
Jim Z Mai,Michael R Sargen,Martha S Linet et al.
Jim Z Mai et al.
Plicature and forced approximation technique accelerates second-intention healing after functional nail surgery with favorable cosmetic and functional outcomes: a prospective pilot study [0.03%]
缝折与强行靠拢技术可促进功能性甲床修复术后二期愈合，并获得良好的美容和功能效果：一项前瞻性研究
Joan Ceravalls,Montserrat Salleras Redonnet,Emili Masferrer et al.
Joan Ceravalls et al.
Ixekizumab demonstrates targeted protection against psoriatic arthritis in psoriasis patients: A multi-center retrospective cohort analysis [0.03%]
伊克珠单抗对银屑病患者的靶向保护作用抑制了银屑病关节炎的发生——一项多中心回顾性队列研究
Rahib K Islam,Ryan Chan,Alexander Maltese et al.
Rahib K Islam et al.
Effectiveness and safety of ruxolitinib cream in Chinese patients with nonsegmental vitiligo [0.03%]
芦可替尼乳膏治疗节段性白癜风中国患者的疗效和安全性
He Huang,Yujun Sheng,Min Li et al.
He Huang et al.